LDL cholesterol: Controversies and future therapeutic directions

The Lancet

Volumn 384, Issue 9943, 2014, Pages 607-617

  Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; BOCOCIZUMAB; C REACTIVE PROTEIN; CANAKINUMAB; DARAPLADIB; EVOLOCUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; METHOTREXATE; MIPOMERSEN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG; VARESPLADIB; ANACETRAPIB; BEZAFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; DALCETRAPIB; EVACETRAPIB; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; NICOTINIC ACID; OMEGA 3 FATTY ACID; TORCETRAPIB; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; ARTICLE; CLINICAL PRACTICE; DRUG SAFETY; DRUG TARGETING; GENETICS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INFLAMMATION; INNATE IMMUNITY; LIPID ANALYSIS; LIPID METABOLISM; META ANALYSIS (TOPIC); MONOTHERAPY; PATIENT IDENTIFICATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; DIET THERAPY; EXERCISE; GENE LOCUS; HEREDITY; LIPID TRANSPORT; NONHUMAN; SMOKING CESSATION; THROMBOSIS PREVENTION;

ANIMALS; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84906239708     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61009-6     Document Type: Review

References (101)

1. J Genest Lipoprotein disorders and cardiovascular risk J Inherit Metab Dis 26 2003 267 287
2. JL Goldstein, MS Brown The LDL receptor Arterioscler Thromb Vasc Biol 29 2009 431 438
3. AD Sniderman, S Tsimikas, S Fazio The severe hypercholesterolemia phenotype. Clinical diagnosis, managment, and emerging therapies J Am Coll Cardiol 63 2014 1935 1947
4. J Genest, P Libby Lipoprotein Disorders and Cardiovascular Disease. Braunwald's Heart Disease: a textbook of cardiovascular medicine ninth edition 2012 Elsevier London 975 995
5. S Lewington, G Whitlock, R Clarke et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths Lancet 370 2007 1829 1839
6. JD Horton, JC Cohen, HH Hobbs PCSK9: a convertase that coordinates LDL catabolism J Lipid Res 50 suppl 2009 S172 S177
7. BA Ference, W Yoo, I Alesh et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis J Am Coll Cardiol 60 2012 2631 2639
8. C Baigent, L Blackwell, J Emberson et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Lancet 376 2010 1670 1681
9. B Mihaylova, J Emberson, L Blackwell et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
10. MJ Pencina, AM Navar-Boggan, RB D'Agostino Sr et al. Application of new cholesterol guidelines to a population-based sample N Engl J Med 370 2014 1422 1431
11. GD Norata, CM Ballantyne, AL Catapano New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs Eur Heart J 34 2013 1783 1789
12. SS Martin, MJ Blaha, MB Elshazly et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications J Am Coll Cardiol 62 2013 732 739
13. M Davidson, SX Liu, P Barter et al. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib J Lipid Res 54 2013 467 472
14. SS Martin, MJ Blaha, MB Elshazly et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile JAMA 310 2013 2061 2068
15. S Mora, N Rifai, JE Buring, PM Ridker Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women Clin Chem 55 2009 888 894
16. SS Lund, M Petersen, M Frandsen et al. Agreement between fasting and postprandial LDL cholesterol measured with 3 methods in patients with type 2 diabetes mellitus Clin Chem 57 2011 298 308
17. I Jialal What is the role of the clinical aboratory in the new ACC/AHA guidelines for the treatment of blood cholesterol in adults? Am J Clin Pathol 141 2014 772 773
18. WG Miller, GL Myers, I Sakurabayashi et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures Clin Chem 56 2010 977 986
19. EJ Schaefer, S Otokozawa, M Ai Limitations of direct methods and the reference method for measuring HDL and LDL cholesterol Clin Chem 57 2011 1081 1083
20. S Bansal, JE Buring, N Rifai, S Mora, FM Sacks, PM Ridker Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women JAMA 298 2007 309 316
21. E Di Angelantonio, P Gao, L Pennells et al. Lipid-related markers and cardiovascular disease prediction JAMA 307 2012 2499 2506
22. S Mora, JD Otvos, N Rifai, RS Rosenson, JE Buring, PM Ridker Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women Circulation 119 2009 931 939
23. AV Khera, BM Everett, MP Caulfield et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) Circulation 129 2014 635 642
24. S Mora, RJ Glynn, PM Ridker High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy Circulation 128 2013 1189 1197
25. SM Boekholdt, BJ Arsenault, S Mora et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis JAMA 307 2012 1302 1309
26. AD Sniderman, S Islam, S Yusuf, MJ McQueen Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study Atherosclerosis 225 2012 444 449
27. S Mora, JE Buring, PM Ridker Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events Circulation 129 2014 553 561
28. PM Ridker, A Pradhan, JG MacFadyen, P Libby, RJ Glynn Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial Lancet 380 2012 565 571
29. D Preiss, SR Seshasai, P Welsh et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
30. HM Colhoun, DJ Betteridge, PN Durrington et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
31. SJ Nicholls, CM Ballantyne, PJ Barter et al. Effect of two intensive statin regimens on progression of coronary disease N Engl J Med 365 2011 2078 2087
32. PM Ridker, PW Wilson A trial-based approach to statin guidelines JAMA 310 2013 1123 1124
33. JP Ioannidis More than a billion people taking statins?: potential implications of the new cardiovascular guidelines JAMA 311 2014 463 464
34. PM Ridker, E Danielson, FA Fonseca et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
35. J van der Leeuw, PM Ridker, Y van der Graaf, FL Visseren Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects Eur Heart J 35 2014 837 843
36. NJ Wald, M Simmonds, JK Morris Screening for future cardiovascular disease using age alone compared with multiple risk factors and age PLoS One 6 2011 18742
37. RA Hayward, HM Krumholz Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health Circ Cardiovasc Qual Outcomes 5 2012 2 5
38. KK Ray, JJ Kastelein, SM Boekholdt et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011 Eur Heart J 35 2014 960 968
39. DX Bu, G Griffin, AH Lichtman Mechanisms for the anti-inflammatory effects of statins Curr Opin Lipidol 22 2011 165 170
40. E Braunwald Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials Eur Heart J 33 2012 430 432
41. PS Sever, NR Poulter, CL Chang et al. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm JACC 62 2012 717 729
42. SE Nissen, EM Tuzcu, P Schoenhagen et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease N Engl J Med 352 2005 29 38
43. R Puri, SE Nissen, P Libby et al. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy Circulation 128 2013 2395 2403
44. A Tawakol, ZA Fayad, R Mogg et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study J Am Coll Cardiol 62 2013 909 917
45. A Varbo, M Benn, A Tybjaerg-Hansen, BG Nordestgaard Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation Circulation 128 2013 1298 1309
46. M Seed, DJ Betteridge, J Cooper et al. Normal levels of inflammatory markers in treated patients with familial hypercholesterolaemia: a cross-sectional study JRSM Cardiovasc Dis 1 2012 1 9
47. G Mingrone, S Panunzi, A De Gaetano et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes N Engl J Med 366 2012 1577 1585
48. L Sjostrom, M Peltonen, P Jacobson et al. Bariatric surgery and long-term cardiovascular events JAMA 307 2012 56 65
49. WE Boden, JL Probstfield, T Anderson et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
50. HPS2-THRIVE Collaborative Group Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 2014 203 212
51. A Keech, RJ Simes, P Barter et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
52. HN Ginsberg, MB Elam, LC Lovato et al. Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
53. SJ Robins, D Collins, JT Wittes et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial JAMA 285 2001 1585 1591
54. M Yokoyama, H Origasa, M Matsuzaki et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 369 2007 1090 1098
55. J Bosch, HC Gerstein, GR Dagenais et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia N Engl J Med 367 2012 309 318
56. D Kromhout, EJ Giltay, JM Geleijnse n-3 fatty acids and cardiovascular events after myocardial infarction N Engl J Med 363 2010 2015 2026
57. MC Roncaglioni, M Tombesi, F Avanzini et al. n-3 fatty acids in patients with multiple cardiovascular risk factors N Engl J Med 368 2013 1800 1808
58. JJ Kastelein, F Akdim, ES Stroes et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia N Engl J Med 358 2008 1431 1443
59. CP Cannon, RP Giugliano, MA Blazing et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes Am Heart J 156 2008 826 832
60. C Baigent, MJ Landray, C Reith et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
61. PJ Barter, M Caulfield, M Eriksson et al. Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
62. GG Schwartz, AG Olsson, M Abt et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
63. DJ Rader, EM de Goma Future of cholesteryl ester transfer protein inhibitors Ann Rev Med 65 2014 385 403
64. E Wong, T Goldberg Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia P T 39 2014 119 122
65. FJ Raal, RD Santos, DJ Blom et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 998 1006
66. EA Stein, R Dufour, C Gagne et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease Circulation 126 2012 2283 2292
67. MP McGowan, JC Tardif, R Ceska et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy PLoS One 7 2012 e49006
68. FJ Raal Lomitapide for homozygous familial hypercholesterolaemia Lancet 381 2013 7 8
69. M Cuchel, LT Bloedon, PO Szapary et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia N Engl J Med 356 2007 148 156
70. M Cuchel, EA Meagher, H du Toit Theron et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study Lancet 381 2013 40 46
71. RJ Smith, WR Hiatt Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder JAMA Intern Med 173 2013 1491 1492
72. NG Seidah, A Prat The biology and therapeutic targeting of the proprotein convertases Nat Rev Drug Discov 11 2012 367 383
73. JC Cohen, E Boerwinkle, TH Mosley Jr, HH Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
74. M Abifadel, M Varret, JP Rabes et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat Genet 34 2003 154 156
75. MJ Koren, R Scott, JB Kim et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Lancet 380 2012 1995 2006
76. D Sullivan, AG Olsson, R Scott et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial JAMA 308 2012 2497 2506
77. EA Stein, D Gipe, J Bergeron et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 2012 29 36
78. EA Stein, S Mellis, GD Yancopoulos et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N Engl J Med 366 2012 1108 1118
79. JM McKenney, MJ Koren, DJ Kereiakes, C Hanotin, AC Ferrand, EA Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353
80. RP Giugliano, NR Desai, P Kohli et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 380 2012 2007 2017
81. EM Roth, JM McKenney, C Hanotin, G Asset, EA Stein Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 2012 1891 1900
82. DJ Blom, T Hala, M Bolognese et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia N Engl J Med 370 2014 1809 1819
83. NR Desai, P Kohli, RP Giugliano et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial Circulation 128 2013 962 969
84. F Raal, R Scott, R Somaratne et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2417
85. EA Stein, N Honarpour, SM Wasserman, F Xu, R Scott, FJ Raal Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia Circulation 128 2013 2113 2120
86. E Stroes, D Colquhoun, D Sullivan et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: The GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab J Am Coll Cardiol 63 2014 2541 2548
87. J Hsia, JG MacFadyen, J Monyak, PM Ridker Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin The JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) J Am Coll Cardiol 57 2011 1666 1675
88. JS McKinney, WJ Kostis Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials Stroke 43 2012 2149 2156
89. K Fitzgerald, M Frank-Kamenetsky, S Shulga-Morskaya et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial Lancet 383 2014 60 68
90. CM Ballantyne, MH Davidson, DE Macdougall et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial J Am Coll Cardiol 62 2013 1154 1162
91. MJ Gutierrez, NL Rosenberg, DE Macdougall et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus Arterioscler Thromb Vasc Biol 34 2014 676 683
92. HE Bays, S Schwartz, T Littlejohn 3rd MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin J Clin Endocrinol Metab 96 2011 2889 2897
93. YJ Choi, BK Roberts, X Wang et al. Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia Atherosclerosis 270 2012 470 476
94. CJ Willer, EM Schmidt, S Sengupta et al. Discovery and refinement of loci associated with lipid levels Nat Genet 45 2013 1274 1283
95. DI Chasman, F Giulianini, J MacFadyen, BJ Barratt, F Nyberg, PM Ridker Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial Circ Cardiovasc Genet 5 2012 257 264
96. P Duewell, H Kono, KJ Rayner et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals Nature 464 2010 1357 1361
97. CA Dinarello, A Simon, JW van der Meer Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases Nat Rev Drug Discov 11 2012 633 652
98. AD Hingorani, JP Casas The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis Lancet 379 2012 1214 1224
99. N Sarwar, AS Butterworth, DF Freitag et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies Lancet 379 2012 1205 1213
100. PM Ridker, TF Luscher Anti-inflammatory therapies for cardiovascular disease Eur Heart J 35 2014 1782 1791
101. I Tabas, CK Glass Anti-inflammatory therapy in chronic disease: challenges and opportunities Science 339 2013 166 172